Wednesday, December 14th, 2022 from 12:00-1:30pm PST

As we look at the various plant medicines that can offer health and healing benefits, one that comes to mind (though less mainstream in the current conversation surrounding psychedelics) is ibogaine. Ibogaine has been looked at for its potential in significantly improving many problematic drug use. However, when looking at ibogaine treatment, there are many issues that may arise regarding family support and understanding of the person in treatment: families may expect their loved one to be same as they were before treatment, they may expect an apology for their loved one’s actions before treatment, they may feel obligated to go through treatment themselves, and much more. This emphasizes the importance of folks to understand what ibogaine treatment entails, whether they are the person in treatment or someone in their support group. What happens to the individual after returning home from Ibogaine treatment? What can we do for the person treated and for the people in their support network, both before and after ibogaine treatment, to create the best possible and enduring long-term treatment outcomes? Join us in this forum with Tom Feegel, who is the CEO of Beond, Dr. Thomas Kingsley Brown, who is the Coordinator of the McNair Program at UC San Diego and an advisor to Beond, and Talia Eisenberg, who is cofounder and Chief Marketing Officer of Beond, to get insights to these questions and more.

Tom Feegel is an experienced entrepreneur, founder, and executive of numerous successful venture-backed startup companies, Tom Feegel is CEO of Beond—the world’s premier network of medically based ibogaine treatment facilities for addiction, depression, anxiety, and PTSD. Beond’s mission is help people end chemical dependency and to end the addiction and suicide epidemic with psychotherapeutic treatment and psychedelic plant medicine innovation.

Dr. Thomas Kingsley Brown has been researching, writing about, and speaking about ibogaine treatment for substance dependence since 2009. He led a MAPS-funded study of outcomes for ibogaine treatment at clinics in Mexico from 2010-2012. He has published a review article on ibogaine treatment in Current Drug Abuse Reviews and co-authored an article on the results of the Mexico based study in The American Journal of Drug Abuse and an article on the transformative effects of the ibogaine experience in the Journal of Psychoactive Drugs. He currently works as the Coordinator of the McNair Program at UC San Diego and as an advisor to Beond (https://www.beond.us/).

Talia Eisenberg is a serial entrepreneur focused on developing industry leading consumer facing products & services in the wellness and psychedelics industry. Talia is most excited to democratize access to medically safe, scientifically backed, accelerated and enduring treatment for addiction and trauma utilizing ibogaine and other healing modalities. Featured in the Wall Street Journal, NYTimes, Time and Newsweek magazines for her work on harm reduction, Talia has written about her personal experience with addiction and ibogaine. She earned her MBA in 2018 and lives with her husband and children in Sonoma County, CA. She is cofounder and Chief Marketing Officer of Beond.

This talk will be recorded and immediately available for rewatch for all attendees.

Do you love Chacruna? Want free entry to events, access to our online member community and exclusive events, free merchandise, and much more! Become a member!

Ibogaine Treatment and Effects on Social Relationships: What Can We Expect?